ABION Inc.
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
203400 | KO
Overview
Corporate Details
- ISIN(s):
- KR7203400007
- LEI:
- Country:
- South Korea
- Address:
- 서울특별시 구로구 디지털로 242 한화비즈메트로1차 242915호, 서울특별시
- Website:
- https://abionbio.com/en/
Description
ABION Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative medicines, focusing on first-in-class and best-in-class therapeutics for oncology and viral diseases. The company's lead oncology asset is ABN401, a selective c-Met tyrosine kinase inhibitor (TKI) designed to treat non-small cell lung cancer (NSCLC) with MET mutations, which has shown a favorable safety profile. Another key pipeline candidate is ABN501, a novel monoclonal antibody targeting Claudin-3 for various cancers. Beyond oncology, ABION is developing ABN101, a second-generation Interferon-β formulated as a broad-spectrum anti-viral inhaler for respiratory infections. The company aims to commercialize its assets in global markets through internationally recognized clinical processes.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-12-26 00:00 |
증권발행결과(자율공시)(제3자배정 유상증자)
|
Korean | 5.9 KB | ||
| 2023-12-26 00:00 |
주권관련사채권의취득결정(자율공시)
|
Korean | 25.6 KB | ||
| 2023-12-26 00:00 |
주권관련사채권의취득결정
|
Korean | 36.0 KB | ||
| 2023-12-20 00:00 |
주요사항보고서(유상증자결정)
|
Korean | 25.1 KB | ||
| 2023-12-18 00:00 |
주요사항보고서(타법인주식및출자증권양수결정)
|
Korean | 26.7 KB | ||
| 2023-12-18 00:00 |
주요사항보고서(유상증자결정)
|
Korean | 31.5 KB | ||
| 2023-12-15 00:00 |
주주명부폐쇄기간또는기준일설정
|
Korean | 4.3 KB | ||
| 2023-12-15 00:00 |
[기재정정]주식매수선택권부여에관한신고
|
Korean | 19.8 KB | ||
| 2023-12-15 00:00 |
[기재정정]주식매수선택권부여에관한신고
|
Korean | 20.0 KB | ||
| 2023-12-15 00:00 |
[기재정정]주식매수선택권부여에관한신고
|
Korean | 19.9 KB | ||
| 2023-12-06 00:00 |
투자판단관련주요경영사항(국책과제 선정-정밀의료 기반의 c-Met 표적 항암제 ABN401의 글로벌 임상2상 연구)
|
Korean | 8.2 KB | ||
| 2023-11-14 00:00 |
분기보고서 (2023.09)
|
Korean | 1.2 MB | ||
| 2023-10-26 00:00 |
기업설명회(IR)개최
|
Korean | 6.9 KB | ||
| 2023-10-16 00:00 |
전환가액의조정
|
Korean | 11.2 KB | ||
| 2023-10-04 00:00 |
기타주요경영사항
|
Korean | 3.9 KB |
Automate Your Workflow. Get a real-time feed of all ABION Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ABION Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ABION Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
